person

Johannes D.

Country
Germany
Department
Medizinische Klinik und Poliklinik II

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
132
Sites with multiple studies

Has run more than one trial at 132 of 289 partner sites.

Specializations

Lymphoma Research

The investigator specializes in treating various forms of B-cell lymphomas, with particular focus on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Their research encompasses both newly diagnosed cases and relapsed/refractory disease states.

  • Aggressive B-cell lymphomas
  • Marginal zone lymphoma
  • Non-Hodgkin lymphoma variants

Research activities include evaluation of novel therapeutic combinations for enhanced treatment outcomes in lymphoma patients.

Therapeutic Innovation

The investigator explores innovative treatment approaches using bispecific antibodies and antibody-drug conjugates. Their work includes assessment of novel agents such as epcoritamab, mosunetuzumab, and tafasitamab.

  • Combination therapy strategies
  • Immunotherapy applications
  • Novel therapeutic agents

Focus areas include development of chemotherapy-light treatment approaches for specific patient populations.

Specialized Treatment Areas

The investigator conducts research in chronic lymphocytic leukemia and small lymphocytic lymphoma, with emphasis on treatment-resistant cases. Their work extends to investigating therapeutic options for elderly patients and those unsuitable for standard treatment regimens.

  • Treatment-resistant diseases
  • Age-specific therapeutic approaches
  • Alternative treatment strategies

Clinical investigations include assessment of safety and efficacy in various B-cell malignancies.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.